Beam Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	156.04	139.74	63.52	377.71	60.92	51.84
Revenue Growth	158.89%	120.01%	-83.18%	520.01%	17.51%	215916.67%
Cost of Revenue	408.66	409.62	367.56	437.38	311.59	232.13
Gross Profit	-252.63	-269.88	-304.04	-59.67	-250.67	-180.29
Selling, General & Admin	125.4	113.82	111.53	116.81	87.81	57.22
Operating Expenses	125.4	113.82	111.53	116.81	87.81	57.22
Operating Income	-378.02	-383.69	-415.57	-176.49	-338.48	-237.51
Interest Expense	-	-	-	-	-	-0.01
Interest & Investment Income	38.9	43.73	49.09	46.68	15.3	-
Earnings From Equity Investments	255.15	255.15	-	-	-25.5	-
Other Non Operating Income (Expenses)	-5.5	0.7	2.27	7.5	23.9	-1
EBT Excluding Unusual Items	-89.48	-84.11	-364.2	-122.31	-324.78	-238.52
Gain (Loss) on Sale of Investments	2.42	3.94	-14.09	-18.59	20.2	17.69
Other Unusual Items	0.54	0.18	1.59	9.74	18.9	5.15
Pretax Income	-86.52	-79.99	-376.7	-131.16	-285.68	-370.64
Income Tax Expense	-	-	0.04	1.37	3.41	-
Earnings From Continuing Operations	-86.52	-79.99	-376.74	-132.53	-289.09	-370.64
Net Income	-86.52	-79.99	-376.74	-132.53	-289.09	-370.64
Net Income to Common	-86.52	-79.99	-376.74	-132.53	-289.09	-370.64
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	103	99	82	77	70	64
Shares Outstanding (Diluted)	103	99	82	77	70	64
Shares Change	16.29%	20.16%	6.69%	10.19%	9.01%	37.44%
EPS (Basic)	-0.84	-0.81	-4.58	-1.72	-4.13	-5.77
EPS (Diluted)	-0.84	-0.81	-4.58	-1.72	-4.13	-5.77
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-372.77	-360.05	-356.19	-182.93	-26.42	-113.08
Free Cash Flow Per Share	-3.61	-3.64	-4.33	-2.37	-0.38	-1.76
Gross Margin	-161.91%	-193.12%	-	-15.80%	-	-
Operating Margin	-242.27%	-274.57%	-654.25%	-46.73%	-555.61%	-458.13%
Profit Margin	-55.45%	-57.24%	-593.13%	-35.09%	-474.54%	-714.91%
Free Cash Flow Margin	-238.90%	-257.65%	-560.77%	-48.43%	-43.38%	-218.11%
EBITDA	-355.78	-361.4	-393.64	-156.47	-324.33	-230.06
EBITDA Margin	-228.01%	-258.62%	-	-41.43%	-	-
D&A For EBITDA	22.24	22.29	21.93	20.01	14.15	7.45
EBIT	-378.02	-383.69	-415.57	-176.49	-338.48	-237.51
EBIT Margin	-242.27%	-274.57%	-	-46.73%	-	-

SEC Filings: 10-K · 10-Q